Y-mAbs Therapeutics (NASDAQ:YMAB) Coverage Initiated by Analysts at Oppenheimer

Oppenheimer started coverage on shares of Y-mAbs Therapeutics (NASDAQ:YMAB) in a research report released on Monday, Marketbeat Ratings reports. The brokerage issued an outperform rating and a $23.00 price target on the stock.

Other equities analysts have also recently issued research reports about the company. Canaccord Genuity Group reiterated a “buy” rating and issued a $26.00 price target on shares of Y-mAbs Therapeutics in a report on Tuesday, August 13th. BMO Capital Markets reduced their price objective on shares of Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 13th. Canaccord Genuity Group raised Y-mAbs Therapeutics to a “strong-buy” rating in a research note on Tuesday, August 13th. Morgan Stanley dropped their price objective on shares of Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating on the stock in a report on Tuesday, August 13th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $20.00 target price on shares of Y-mAbs Therapeutics in a research note on Monday, September 9th. One analyst has rated the stock with a sell rating, seven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Y-mAbs Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $21.38.

Y-mAbs Therapeutics Trading Down 2.9 %

YMAB stock opened at $10.54 on Monday. The firm has a market cap of $472.09 million, a P/E ratio of -19.52 and a beta of 0.68. Y-mAbs Therapeutics has a 1-year low of $5.17 and a 1-year high of $20.90. The business’s 50 day moving average is $13.82 and its 200-day moving average is $12.95.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its quarterly earnings data on Friday, November 8th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.02). The firm had revenue of $18.46 million for the quarter, compared to the consensus estimate of $23.38 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. During the same period in the prior year, the company posted ($0.18) earnings per share. Sell-side analysts forecast that Y-mAbs Therapeutics will post -0.65 EPS for the current year.

Insider Buying and Selling

In related news, insider Thomas Gad sold 30,000 shares of the stock in a transaction on Monday, September 16th. The shares were sold at an average price of $12.97, for a total transaction of $389,100.00. Following the transaction, the insider now directly owns 67,681 shares of the company’s stock, valued at $877,822.57. This represents a 30.71 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Joris Wilms sold 5,000 shares of the firm’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $14.69, for a total value of $73,450.00. Following the completion of the sale, the chief operating officer now owns 30,600 shares of the company’s stock, valued at approximately $449,514. This represents a 14.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 100,000 shares of company stock worth $1,338,100 in the last ninety days. Company insiders own 22.50% of the company’s stock.

Institutional Investors Weigh In On Y-mAbs Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in Y-mAbs Therapeutics during the 3rd quarter worth approximately $44,000. Ameritas Investment Partners Inc. lifted its stake in Y-mAbs Therapeutics by 39.9% during the 1st quarter. Ameritas Investment Partners Inc. now owns 3,701 shares of the company’s stock valued at $60,000 after acquiring an additional 1,056 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of Y-mAbs Therapeutics by 66.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,572 shares of the company’s stock worth $113,000 after acquiring an additional 3,416 shares in the last quarter. Intech Investment Management LLC bought a new position in shares of Y-mAbs Therapeutics during the third quarter valued at about $133,000. Finally, SG Americas Securities LLC bought a new stake in Y-mAbs Therapeutics in the 3rd quarter worth about $178,000. Institutional investors and hedge funds own 70.85% of the company’s stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.